Practical advice for avoidance of pain associated with insertion of intrauterine contraceptives

Journal of Family Planning and Reproductive Health Care

Volumn 40, Issue 1, 2014, Pages 54-60

  Bahamondes, Luis ^a   Mansour, Diana ^b   Fiala, Christian ^c,d   Kaunitz, Andrew M ^e   Gemzell Danielsson, Kristina ^d  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c Gynmed Clinic   (Austria)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER INTRAUTERINE DEVICE; DICLOFENAC; LEVONORGESTREL; LIDOCAINE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT;

ANALGESIA; COUNSELING; DRUG EFFICACY; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; LOCAL ANESTHESIA; NOCICEPTION; PAIN; PRACTICE GUIDELINE; REVIEW; TENACULUM; UTERINE CERVIX DILATATION;

EID: 84892598013     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1136/jfprhc-2013-100636     Document Type: Review

References (28)

1. Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397-404.
2. Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012;366:1998-2007.
3. Lyus R, Lohr P, Prager S. Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women. Contraception 2010;81:367-371.
4. National Institute for Health and Care Excellence. Clinical Knowledge Summaries. UK Medical Eligibility Criteria for use of the levonorgestrel- releasing intrauterine system. 2011. http://www.cks.nhs.uk/contraception-ius- iud/management/scenario-intrauterine-system/starting-a-levonorgestrel-releasing- ius/uk-medical-eligibility-criteria [accessed 26 November 2012].
5. National Institute for Health and Care Excellence. Clinical Knowledge Summaries. UK Medical Eligibility Criteria for use of copper intrauterine devices. 2011. http://www.cks.nhs.uk/contraception-ius-iud/management/scenario- intrauterine-device/starting-an-iud/uk-medical-eligibility-criteria [accessed 26 November 2012].
6. World Health Organization. Medical Eligibility Criteria for Contraceptive Use (4th edn). 2010. http://www.who.int/reproductivehealth/publications/family- planning/9789241563888/en/ [accessed 26 November 2012].
7. Centers for Disease Control and Prevention. MMWR Early Release: U.S. Medical Eligibility Criteria for Contraceptive Use, Vol. 59. 2010. http://www.cdc.gov/mmwr/pdf/rr/rr59e0528.pdf [accessed 26 November 2012].
8. ACOG Committee on Practice Bulletins-Gynecology. Committee Opinion No. 539: Adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol 2012;120:983-988.
9. Bahamondes MV, Hidalgo MM, Bahamondes L, et al. Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas. Contraception 2011;84: e11-e16.
10. Hubacher D, Reyes V, Lillo S, et al. Pain from copper intrauterine device insertion: randomized trial of prophylactic ibuprofen. Am J Obstet Gynecol 2006;195:1272-1277.
11. Lassner KJ, Chen CH, Kropsch LA, et al. Comparative study of safety and efficacy of IUD insertions by physicians and nursing personnel in Brazil. Bull Pan Am Health Organ 1995;29:206-215.
12. Chi IC, Galich LF, Tauber PF, et al. Severe pain at interval IUD insertion: a case-control analysis of patient risk factors. Contraception 1986;34:483-495.
13. Brockmeyer A, Kishen M, Webb A. Experience of IUD/IUS insertions and clinical performance in nulliparous women-a pilot study. Eur J Contracept Reprod Health Care 2008;13:248-254.
14. Marions L, Lövkvist L, Taube A, et al. Use of the levonorgestrel releasing-intrauterine system in nulliparous women - a non-interventional study in Sweden. Eur J Contracept Reprod Health Care 2011;16:126-134.
15. Heikinheimo O, Inki P, Kunz M, et al. Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system. Contraception 2010;81:481-486.
16. Allen RH, Bartz D, Grimes DA, et al. Interventions for pain with intrauterine device insertion. Cochrane Database Syst Rev 2009;3:CD007373.
17. Fiala C, Gemzell-Danielsson K, Tang OS, et al. Cervical priming with misoprostol prior to transcervical procedures. Int J Gynaecol Obstet 2007;99(Suppl. 2):S168-S171.
18. Gemzell-Danielsson K, Mansour D, Fiala C, et al. Management of pain associated with the insertion of intrauterine contraceptives. Hum Reprod Update 2013;19:419-427.
19. Murty J. Use and effectiveness of oral analgesia when fitting an intrauterine device. J Fam Plann Reprod Health Care 2003;29:150-151.
20. Zhou L, Harrison-Woolrych M, Coulter DM. Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena). Pharmacoepidemiol Drug Saf 2003;12:371-377.
21. Faúndes A, Alvarez F, Díaz J. A Latin American experience with levonorgestrel IUD. Ann Med 1993;25:149-153.
22. Sääv I, Aronsson A, Marions L, et al. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial. Hum Reprod 2007;22:2647-2652.
23. Dijkhuizen K, Dekkers OM, Holleboom CA, et al. Vaginal misoprostol prior to insertion of an intrauterine device: an RCT. Hum Reprod 2011;26:323-329.
24. Gupta JK, Johnson N. Effect of mifepristone on dilatation of the pregnant and non-pregnant cervix. Lancet 1990;335: 1238-1240.
25. Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit. FSRH Guidance (Nov 2007) Intrauterine Contraception. 2007. http://www.fsrh.org/pdfs/CEUGuidanceIntrauterineContraceptionNov07.pdf [accessed 14 March 2013].
26. Maguire K, Davis A, Rosario Tejeda L, et al. Intracervical lidocaine gel for intrauterine device insertion: a randomized clinical trial. Contraception 2012;86:214-219.
27. McNicholas CP, Madden T, Zhao Q, et al. Cervical lidocaine for IUD insertion pain: a randomized controlled trial. Am J Obstet Gynecol 2012;207:384.e1-e6.
28. Nadelberg R. Paracervical Block. Boston Scientific Corporation. 2007. http://www.bostonscientific.com [accessed 26 November 2012].